Surgical and Medical Intervention Options for Dysphagia in Oculopharyngeal Muscular Dystrophy: A Systematic Review
Dysphagia · 06.11.2026
DOI: 10.1007/s00455-026-11022-6 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dysphagia, online erschienen am 06.11.2026. Verfasst von Kaitlynn Meier-Ross und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. Die Arbeit nennt 80 Literaturangaben. Gefördert von: CIHR, Physicians' Services Incorporated Foundation, Muscular Dystrophy Canada.
Themen: Dysphagie
Abstract (Originalsprache)
Oculopharyngeal muscular dystrophy (OPMD) is an inherited degenerative muscle disease that features dysphagia among its earliest and most problematic symptoms. There is limited information on the optimal type and timing of dysphagia treatment in OPMD. We aimed to consolidate information regarding outcomes of treatment by botulinum toxin injection (BT), esophageal dilatation (ED), and cricopharyngeal myotomy (CPM) in a systematic review (PROSPERO Registration CRD42025575703). Electronic databases (MEDLINE, Embase, CINAHL, CENTRAL, Scopus, Web of Science) were systematically searched for studies describing outcomes of BT, ED, or CPM treatment in adults with OPMD, published from database inception to November 5, 2025. Eligibility criteria were met by 40 out of 2920 original titles identified by the search, with 28 (BT), 31 (ED), and 405 (CPM) patients having treatment outcomes described. Treatment success rates were approximately 59% (BT), 71% (ED), and 91% (CPM). Rates of complication were ~ 44% (BT), < 1% (ED), < 37% (CPM). Median durations of treatment effectiveness were ~ 6 months (BT), ~ 16 months (ED), and ~ 6 years (CPM). In summary, while CPM is the most invasive procedure, it leads to the longest-lasting and most complete improvement of dysphagia. BT and ED are less invasive and can improve early dysphagia symptoms but typically require ongoing treatments for sustained symptom abatement. Compared to BT, ED had a higher rate and duration of effectiveness, and lower rate of complications. Severe pharyngeal impairment can be associated with poor outcomes with CPM, and may require alternative methods, such as modified diet or gastrostomy tube to support nutrition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Department of Medicine (Gastroenterology), The Ottawa Hospital/ University of Ottawa, Ottawa, ON, Canada.
- Department of Otolaryngology - Head and Neck Surgery, The Ottawa Hospital/ University of Ottawa, Ottawa, ON, Canada.
- Department of Surgery, Division of Thoracic Surgery, The Ottawa Hospital/University of Ottawa, Ottawa, ON, Canada.
- Library, University of Ottawa, Ottawa, ON, Canada.
Förderung
- CIHR
- Physicians' Services Incorporated Foundation
- Muscular Dystrophy Canada
- ALS Society of Canada
- University of Ottawa
- Government of Canada
- Eric Poulin ALS Translational Research Fund
- Canadian Institutes of Health Research
Zitieren
APA
Meier-Ross, K., Chakraborty, S., Smith, I. C., Canning, S., Campbell, R., Villeneuve, P. J., Ly, V., & Warman-Chardon, J. (2026). Surgical and Medical Intervention Options for Dysphagia in Oculopharyngeal Muscular Dystrophy: A Systematic Review. Dysphagia. https://doi.org/10.1007/s00455-026-11022-6
Vancouver
Meier-Ross K, Chakraborty S, Smith IC, Canning S, Campbell R, Villeneuve PJ, et al. Surgical and Medical Intervention Options for Dysphagia in Oculopharyngeal Muscular Dystrophy: A Systematic Review. Dysphagia. 2026. doi:10.1007/s00455-026-11022-6
BibTeX
@article{MeierRoss2026,
author = {Meier-Ross, Kaitlynn and Chakraborty, Shaoni and Smith, Ian C and Canning, Stephanie and Campbell, Ross and Villeneuve, Patrick James and Ly, Valentina and Warman-Chardon, Jodi},
title = {Surgical and Medical Intervention Options for Dysphagia in Oculopharyngeal Muscular Dystrophy: A Systematic Review},
journal = {Dysphagia},
year = {2026},
doi = {10.1007/s00455-026-11022-6}
}
EUVIMED